Drug Search Results
More Filters [+]

Aripiprazole

Alternative Names: aripiprazole, abilify, opc-14597, abilify maintena, bms-337039, abilify maintena kit, ARIPIPRAZOL, aripiprazol
Latest Update: 2024-12-17
Latest Update Note: Clinical Trial Update

Product Description

Aripiprazole is a medication that works in the brain to treat schizophrenia. It is also known as a second generation antipsychotic (SGA) or atypical antipsychotic. Aripiprazole rebalances dopamine and serotonin to improve thinking, mood, and behavior. (Sourced from: https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Aripiprazole-(Abilify))

Mechanisms of Action: D2 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Bipolar Disorder | Schizophrenia | Bipolar Disorder | Depressive Disorder | Depressive Disorder, Major | Bipolar Disorder | Depressive Disorder | Depressive Disorder, Major | Autism Spectrum Disorder | Tic Disorders | Schizophrenia

Known Adverse Events: Pain Unspecified | Schizophrenia | Bipolar Disorder | Tremor | Insomnia | Constipation | Depressive Disorder | Depressive Disorder, Major | Autism Spectrum Disorder | Tic Disorders | Dizziness | Headache | Lethargy | Nasopharyngitis | Pharyngitis

Company: Otsuka
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Aripiprazole

Countries in Clinic: China, Korea, Unknown Location

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Bipolar Disorder|Rett Syndrome|Schizophrenia|Tourette Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

KH734-60101

P3

Not yet recruiting

Schizophrenia

2026-06-01

APOLLO

P3

Recruiting

Bipolar Disorder

2025-11-01

CTR20212366

P1

Not yet recruiting

Schizophrenia

None

CTR20201480

P1

Not yet recruiting

Schizophrenia

None

Recent News Events